What Happens If a Transplanted Liver Fails? Causes, Rescue and Re-transplant

A failing transplanted liver is a question, not a verdict. Most abnormal results after transplant have a treatable cause — rejection, infection, a blocked hepatic artery, a narrowed bile duct, drug toxicity or recurrence of the original disease. Only about 5–7% of recipients ever need a second transplant, and in recent registry series two-thirds to four-fifths of those are alive five years later.
— Dr Chetan Kalal, DM Hepatology, Gleneagles Hospital Mumbai

“Doctor, what happens if the new liver also fails?” It is one of the most frightening questions a transplant family can ask. My answer is always the same: it depends on why the graft is failing. There is no single treatment called “treatment for graft failure.” The first step is always understanding what’s actually happening to the graft, and whether the process is reversible.

One point I make very clear, every time: abnormal liver tests do not automatically mean the transplanted liver has failed. This article sets out how I think when a graft is in trouble — the causes by timing, what can be rescued and how, when re-transplantation enters the conversation, and what I say to a family when it does. It is educational decision support, not a plan for any individual; your transplant team has the scans and the biopsy, and their judgement overrides anything here. For how long a well-functioning graft can be expected to serve, and what keeps it that way, read the companion post on how long a transplanted liver lasts.

Graft dysfunction is rarely one thing — and timing narrows it

Dysfunction can be multifactorial — rejection, infection, vascular or biliary complications, drug toxicity, recurrence of the original disease, metabolic injury, or some combination of these. Treatment has to be directed at the actual cause, not at “graft failure” as a single category. The calendar is the first clue. In a US analysis of 49,288 recipients, 5.5% eventually needed a second liver; of those re-transplants, 19% happened in the first week, 20% in the rest of the first month and 33% during the remainder of the first year — each window with its own characteristic cause.

The first week: a graft slow to start, or no start at all. The working definition of early allograft dysfunction, validated by Olthoff and colleagues across three US centres, is any one of: bilirubin of 10 mg/dL or more on day seven, INR of 1.6 or more on day seven, or a transaminase above 2,000 IU/L in the first week. By that definition 23% of deceased-donor grafts qualified. Most recovered — but 26% of them were eventually lost, against 3.5% of grafts that started cleanly, and the recipients were ten times more likely to die. At the far end of that spectrum is primary non-function, the graft that never works and must be replaced urgently. Living-donor grafts carry an additional early hazard: a graft too small for the recipient. The accepted lower limit for graft-to-recipient weight ratio is 0.8%, and a Medanta series of 1,321 consecutive adult living-donor transplants reported small-for-size syndrome in 2.8%, with inflow modulation used selectively below that threshold.

The first weeks: the hepatic artery. A bile duct has only one blood supply after transplant — the hepatic artery — so a clot in that vessel is the complication every transplant surgeon dreads. A systematic review of 71 studies and 21,822 transplants put early hepatic artery thrombosis at 4.4% overall and 2.9% in adults, detected at a median of day seven. More than half of those grafts had to be replaced and one patient in three died. Variant arterial anatomy, arterial conduits and re-transplantation itself were among the risk factors. Daily Doppler ultrasound in the first days is not ritual; it is the only way to catch this while the graft can still be saved.

The first months: bile ducts, rejection, infection. Biliary strictures are the commonest late technical problem in living-donor transplantation; in a large Indian series of 2,956 adult recipients, 11.6% developed one, and 77% were treated endoscopically first. Acute cellular rejection peaks in the same period and is confirmed on biopsy, never assumed — I have set out its diagnosis and treatment in my post on liver transplant rejection. Infection, above all cytomegalovirus, can mimic both and is covered in the first-year guide.

Years later: chronic rejection, recurrence, missed medicines. Beyond the first year the picture changes. Ductopenic chronic rejection, recurrence of the original disease — alcohol, autoimmune hepatitis, fatty liver, cancer — and the quiet erosion of adherence are the late threats, and they are the subject of the companion post.

Sometimes the graft can be rescued

If rejection is responsible — the approach may involve intensifying or modifying immunosuppression. In selected severe or steroid-resistant cases, antibody therapies such as ATG (anti-thymocyte globulin) may be considered; the details are in the rejection post above.

If severe kidney dysfunction develops, including acute kidney injury — CRRT (continuous renal replacement therapy) may be needed as supportive treatment while the underlying problem is addressed.

If infection is driving dysfunction — the priority is identifying and treating the infection while carefully balancing immunosuppression, since the two pull in opposite directions and need careful management together.

If there’s a vascular or biliary complication — an appropriate interventional or surgical approach may be required: re-exploration or endovascular treatment for an arterial clot caught early, endoscopic or percutaneous stenting for a stricture.

So when abnormal liver tests appear after transplant, the response isn’t “the transplant has failed.” The questions are: what’s causing the dysfunction, is it reversible, and what can be done right now to rescue the graft?

And sometimes re-transplantation becomes necessary

If the graft has sustained irreversible injury despite appropriate treatment, re-transplantation may become the definitive option in carefully selected patients. That decision is never made because one blood test came back abnormal.

It requires reassessing the whole patient: why the first graft failed, current liver and kidney function, infection status, cardiovascular fitness, nutritional and functional condition, medication adherence, psychosocial support, and whether a second transplant is likely to provide meaningful benefit.

The registries tell families two honest things at once. A second transplant is uncommon — 5.5% of recipients in the US analysis above, 6.7% of adult transplants in Australia and New Zealand over thirty years, where the leading reasons were vessel thrombosis (29%), disease recurrence (21%) and graft non-function (15%). And its results are worse than a first transplant but far from futile: in Australia and New Zealand since 2000, 89% of re-transplanted patients were alive at one year, 81% at five and 74% at ten; in the US registry, 78% at one year and 64% at five for 2022, with being on life support beforehand, the number of previous transplants, age, frailty and donor factors driving the difference. The lesson inside those numbers is about timing. The patient who is re-listed while still walking does well; the patient re-transplanted from the ICU on a ventilator does not.

In India the conversation has an extra layer. Because the large majority of our transplants use a living donor, a second graft usually means a second donor — often from the same family, which has already given once — or a place on the deceased-donor waiting list, where a failing graft is prioritised but supply is thin. Both paths deserve a frank conversation, and a second opinion is reasonable at this point, not disloyal.

When the graft cannot be saved: a case I remember

Not every graft dysfunction can be reversed.

One case that stays with me involved a patient who underwent living-donor liver transplantation for autoimmune hepatitis. Roughly three weeks after transplant, the patient developed significant graft dysfunction — a complex vascular problem involving portal-vein arterialisation, requiring urgent multidisciplinary management. Anticoagulation was started and the patient underwent surgical re-exploration in an attempt to salvage the graft.

The graft did not recover. Re-transplantation was considered. But the patient’s condition continued to deteriorate, sepsis developed, and despite further intensive management, the patient died.

I include this case because families deserve to know that liver transplantation is extraordinarily successful — but it is not risk-free. Sometimes a problem is identified and the graft is successfully rescued. Sometimes aggressive intervention happens and the injury has already progressed beyond recovery. And sometimes, even when re-transplantation is considered, a patient’s condition deteriorates to the point where another transplant is no longer a realistic or safe option. That’s one of the hardest realities in transplant medicine.

What I’d want a family to understand in that situation

I would not tell a family everything will definitely be fine when the situation is critical. I would explain it honestly:

“We have a serious problem with the graft. We are doing everything possible to understand the cause and see whether we can salvage it. Re-transplantation may need to be considered, but first we have to stabilise the patient and see how the graft responds. I will tell you honestly as the situation evolves.”

If the graft ultimately becomes irreversibly damaged, the conversation has to change. There’s no value in giving a family false hope — but there’s equally no value in declaring defeat prematurely. Throughout, the transplant team keeps asking: can we treat the cause? Can we rescue the graft? Can we support the patient long enough for recovery? If the graft can’t recover, is re-transplantation technically and medically possible?

In this patient, despite intervention, re-exploration and consideration of re-transplantation, the clinical course progressed to sepsis, and the patient died. That outcome is difficult to discuss — but it’s part of transplant medicine too. A responsible transplant physician has to know not only how to fight for a graft, but how to recognise when the limits of medicine have been reached, and communicate that honestly with the family.

The pathway, honestly

The path after graft dysfunction is not:

abnormal test → failed liver → re-transplant.

It’s:

abnormality → identify the cause → treat what’s reversible → support failing organs when necessary → reassess graft recovery → consider re-transplantation only if irreversible failure is established.

That’s a more clinically honest way to understand graft failure than the version most patients arrive expecting.

Why regular follow-up matters here specifically

This is exactly why transplant recipients are asked not to wait for symptoms before reporting concerns. Regular follow-up can catch graft dysfunction early — while there may still be something meaningful that can be done to change the outcome. The earlier a cause is identified, the more options tend to be on the table. Fever, jaundice, dark urine, reduced urine output or a rising enzyme on a routine report are same-day calls to the team, not items for the next appointment — and no medicine should ever be stopped or changed without them. The warning signs and the follow-up schedule are set out in the first-year guide linked above.

Graft dysfunction is not a single diagnosis with a single answer — it’s a question that has to be investigated properly before any decision gets made. That’s exactly why follow-up doesn’t stop once you’re feeling well. Catching a problem early is often what keeps the options open.

References

1. Olthoff KM, Kulik L, Samstein B, et al. Validation of a current definition of early allograft dysfunction in liver transplant recipients and analysis of risk factors. Liver Transpl. 2010;16(8):943–949. PMID 20677285. doi:10.1002/lt.22091
2. Bekker J, Ploem S, de Jong KP. Early hepatic artery thrombosis after liver transplantation: a systematic review of the incidence, outcome and risk factors. Am J Transplant. 2009;9(4):746–757. PMID 19298450. doi:10.1111/j.1600-6143.2008.02541.x
3. Rana A, Petrowsky H, Kaplan B, et al. Early liver retransplantation in adults. Transpl Int. 2014;27(2):141–151. PMID 24112236. doi:10.1111/tri.12201
4. Jeffrey AW, Delriviere L, McCaughan G, et al. Excellent contemporary graft survival for adult liver retransplantation: an Australian and New Zealand registry analysis from 1986 to 2017. Transplant Direct. 2019;5(8):e472. PMID 31576368. doi:10.1097/TXD.0000000000000920
5. Waller D, Chinnakotla S, Ramanathan K, et al. Liver retransplantation: identifying factors and developing a risk prediction model to predict futility in the modern era. Transplantation. 2025;109(11):1765–1773. PMID 40644633. doi:10.1097/TP.0000000000005462
6. Kwong AJ, Lake JR, Schladt DP, et al. OPTN/SRTR 2024 Annual Data Report: Liver. Am J Transplant. 2026;26(8S1):S214–S320. PMID 42276697. doi:10.1016/j.ajt.2026.05.721. Full chapter: srtr.hrsa.gov/adr/2024/Liver
7. Soin AS, Yadav SK, Saha SK, et al. Is portal inflow modulation always necessary for successful utilization of small volume living donor liver grafts? Liver Transpl. 2019;25(12):1811–1821. PMID 31436885. doi:10.1002/lt.25629
8. Jadaun SS, Nekarakanti PK, Bhatia S, et al. Post-living donor liver transplant biliary strictures: prevalence, predictors, and long-term outcomes in a retrospective study. Clin Transplant Res. 2025;39(1):55–65. PMID 40150918. doi:10.4285/ctr.24.0038
9. Narasimhan G. Living donor liver transplantation in India. Hepatobiliary Surg Nutr. 2016;5(2):127–132. PMID 27115006. doi:10.3978/j.issn.2304-3881.2015.09.01